Actively Recruiting
Effect of High-Intensity Exercise to Attenuate Cognitive Function Limitations and Train Exercise Habits in Older People Living With HIV
Led by University of Alabama at Birmingham · Updated on 2025-12-08
110
Participants Needed
3
Research Sites
239 weeks
Total Duration
On this page
Sponsors
U
University of Alabama at Birmingham
Lead Sponsor
U
University of Colorado, Denver
Collaborating Sponsor
AI-Summary
What this Trial Is About
People aging with HIV are at higher risk for Alzheimer's disease and related dementias, and although physical activity is a promising target to mitigate such risk, this population engages in low levels of physical activity. Few studies have tested cognitive effects of exercise interventions or examined mechanisms of adherence to long-term exercise among diverse samples of midlife and older people with HIV. The current study will leverage an existing R01 to address these gaps and provide implications for development of personalized approaches for the treatment and prevention of cognitive impairment and dementia in older people with HIV.
CONDITIONS
Official Title
Effect of High-Intensity Exercise to Attenuate Cognitive Function Limitations and Train Exercise Habits in Older People Living With HIV
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Confirmed HIV infection
- Sedentary lifestyle with less than 3 days per week of physical activity causing sweat and no regular resistance exercise for 3 months prior
- Fatigue score of 2.0 or higher on screening items
- On current antiretroviral therapy for 12 months or more
- HIV-1 RNA less than 200 copies/mL in past 12 months
- Willingness to participate in supervised exercise 3 times per week for 4 months
- Access to cell phone or email for receiving messages
- Weight less than 450 pounds
- Medical clearance from study healthcare professional
You will not qualify if you...
- Weight over 450 pounds
- Use of sex hormone therapy for 3 months or less (stable doses longer than 3 months allowed)
- Use of other hormone replacement for 3 months or less (stable doses longer than 3 months allowed)
- Anemia with hemoglobin less than 9 g/dL for women or less than 10 g/dL for men
- Diagnosis of mitochondrial disease
- Active substance abuse or other factors preventing safe study participation
- Uncontrolled hypertension with blood pressure over 150/90 mmHg
- Unstable ischemic heart disease or serious arrhythmias without negative follow-up evaluation
- New York Heart Association Class III or IV heart failure or severe heart conditions
- Pulmonary disease requiring supplemental oxygen at rest or during exertion
- Cancer treated with chemotherapy or radiation within 24 weeks prior to enrollment
- Poorly controlled diabetes with hemoglobin A1c over 8.5 or current insulin use
- Surgery, trauma, injury, or fracture within 24 weeks prior affecting baseline function
- Balance impairments affecting functional testing or safe exercise
- Severe orthopedic problems limiting moderate intensity resistance exercise
- Unstable health or inability to safely participate as judged by study clinician
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 3 locations
1
University of Alabama at Birmingham
Birmingham, Alabama, United States, 35294
Not Yet Recruiting
2
University of Colorado Denver
Aurora, Colorado, United States, 80045
Actively Recruiting
3
University of Washington
Seattle, Washington, United States, 98195
Actively Recruiting
Research Team
P
Pariya Wheeler, PhD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
DOUBLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
PREVENTION
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here